Search





Search





Markets
/
Stocks
/
nasdaq-vyne
/

Vyne Therapeutics Inc

VYNE

Add to Watchlist

0.671USD

+0.001+0.09%

Market hours （ET）Quotes delayed by 15 min

22.36MMarket Cap

LossP/E TTM



Vyne Therapeutics Inc

0.671

+0.001+0.09%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Vyne Therapeutics Inc

Currency: USD Updated: 2026-05-14

Key Insights

Vyne Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 175 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 2.00.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Vyne Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

175 / 382

Overall Ranking

312 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Vyne Therapeutics Inc Highlights

StrengthsRisks

VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 34.43% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 570.00K.

Undervalued

The company’s latest PE is -1.08, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 11.08M shares, decreasing 13.12% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 0.00 shares of this stock.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

2.000

Target Price

+198.51%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-14

The current financial score of Vyne Therapeutics Inc is 7.34, ranking 96 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 130.00K, representing a year-over-year increase of 54.76%, while its net profit experienced a year-over-year increase of 59.77%.

Score

Industry at a Glance

Previous score

7.34

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.69

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.87

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.79

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.35

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Vyne Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-05-14

The current valuation score of Vyne Therapeutics Inc is 6.98, ranking 183 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.08, which is -224.80% below the recent high of 1.35 and -322.65% above the recent low of -4.58.

Score

Industry at a Glance

Previous score

6.98

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 175/382

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-14

The current earnings forecast score of Vyne Therapeutics Inc is 7.00, ranking 309 out of 382 in the Biotechnology & Medical Research industry. The average price target is 3.25, with a high of 4.50 and a low of 2.00.

Score

Industry at a Glance

Previous score

7.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

2.000

Target Price

+198.51%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Vyne Therapeutics Inc

VYNE

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Ionis Pharmaceuticals Inc

IONS

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-14

The current price momentum score of Vyne Therapeutics Inc is 4.52, ranking 343 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.70 and the support level at 0.62, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.52

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.001

Buy

RSI(14)

64.667

Neutral

STOCH(KDJ)(9,3,3)

62.547

Neutral

ATR(14)

0.021

High Vlolatility

CCI(14)

67.537

Neutral

Williams %R

28.000

Buy

TRIX(12,20)

0.345

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

0.665

Buy

MA10

0.663

Buy

MA20

0.650

Buy

MA50

0.623

Buy

MA100

0.599

Buy

MA200

0.478

Buy

Institutional Confidence

Currency: USD Updated: 2026-05-14

The current institutional shareholding score of Vyne Therapeutics Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 33.26%, representing a quarter-over-quarter increase of 127.19%. The largest institutional shareholder is The Vanguard, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Shay Capital LLC

1.62M

+229.77%

Anson Funds Management LP.

1.27M

Access Industries, Inc.

1.12M

Nantahala Capital Management, LLC

1.00M

T3 Companies, LLC

945.00K

Delaware Street Capital, L.L.C.

696.47K

Acadian Asset Management LLC

638.49K

+43.03%

KVP Capital Advisors, LP

500.55K

Two Sigma Investments, LP

383.10K

+38.11%

Risk Assessment

Currency: USD Updated: 2026-05-14

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Vyne Therapeutics Inc is 1.71, ranking 277 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 2.00. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.